Evidence map›Paper›PMID 26010956›Full record

ArticlePloS one2015

Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women.

Pascale Ondoa, Raju Gautam, John Rusine, Rene Lutter, Suzanne Jurriaans, Neeltje Kootstra, Etienne Karita, Janneke van de Wijgert

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Comparison of sampling methods to measure HIV RNA viral load in female genital tract secretions.American journal of reproductive immunology (New York, N.Y. : 1989) · 2017
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Pascale OndoaAmsterdam Institute of Global Health and Development (AIGHD), Department of Global Health of the Academic Medical Center, Amsterdam, The Netherlands.
Raju GautamInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
John RusineINTERACT Program, Kigali, Rwanda; National Reference Laboratory, Kigali, Rwanda.
Rene LutterDepartment of Respiratory Medicine of the Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology of the Academic Medical Center, Amsterdam, The Netherlands.
Suzanne JurriaansDepartment of Medical Microbiology of the Academic Medical Center, Amsterdam, The Netherlands.
Neeltje KootstraDepartment of Experimental Immunology of the Academic Medical Center, Amsterdam, The Netherlands.
Etienne KaritaProject San Francisco, Kigali, Rwanda.
Janneke van de WijgertInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Academic Medical Center · NLUniversity of Liverpool · GBAmsterdam Institute for Global Health and Development · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenital viral load (GVL) is the main determinant of sexual transmission of human immune-deficiency virus (HIV). The effect of antiretroviral therapy (ART) on local cervico-vaginal immunological factors associated with GVL is poorly described. We aimed to identify the risk factors of detectable GVL, and the impact of ART on HIV genital shedding and its correlates in a cohort of HIV-infected women, attending HIV care in Kigali, Rwanda. MATERIALS AND

methodsAll participants were evaluated for GVL, plasma viral load (PVL), CD4 count, various sexually-transmitted infections (STIs) at baseline and at month 12. Genital concentration of 19 cytokines and mRNA expression of APOBEC3G and BST2, two host HIV restriction factors, were evaluated at baseline in all participants. Cytokine levels were re-assessed at month 12 only in participants eligible for ART at baseline. Risk factors of GVL ≥ 40 copies/mL at baseline and month 12 were assessed using logistic regression. Effect of 12-month ART on various local and systemic immunological parameters was examined using a paired t-test and McNemar as appropriate.

results96 of the 247 women enrolled in the study were eligible for ART. After 12 months of ART, PVL and GVL decreased to undetectable level in respectively 74 and 88% of treated participants. ART did not affect cytokine levels. HIV genital shedding occurred only when PVL was detectable. At baseline, GVL was independently associated with IL-1β after controlling for PVL, age and N. gonorrhea infection (95% CI 1.32-2.15) and at month 12 with MIP-1β (95% CI 0.96-21.32) after controlling for baseline GVL, PVL and month 12 IL-8.

conclusionSuppressive ART does not necessarily reduce genital level of immune activation. Minimizing all conditions favoring genital inflammation, including active detection and treatment of STIs, might reduce the risk of HIV transmission as supplement to the provision of potent ART.

Indexed as

AdultAntiretroviral Therapy, Highly ActiveAntiviral AgentsCD4 Lymphocyte CountCytokinesFemaleHIV-1HIV InfectionsHumansPlasmaRisk FactorsRNA, MessengerRNA, ViralRwandaVaginaViral LoadAntiviral AgentsCytokinesRNA, MessengerRNA, Viral

Identifiers

PMID26010956
PMCPMC4444210
OpenAlexW378384535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.